ParAllele, Merck to Search for SNPs Linked to Cancer Risk, Drug Response

genomeweb
360dx

ParAllele, Merck to Search for SNPs Linked to Cancer Risk, Drug Response

Jul 07, 2005

NEW YORK, July 7 (GenomeWeb News) - ParAllele BioScience and Merck plan to co-discover SNPs linked to cancer susceptibility, prognosis, or drug response, the companies said today.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

Hologic Refinances Amended Loan and Revolving Credit Agreements
Bristol-Myers Squibb, Boston Medical Center Partner to Study Immuno-Oncology Response, Resistance
OncoImmunity Wins €2.2M in European Funding for Neoantigen Prediction Tech
Autism, Developmental Delay Gene Candidates Compiled From De Novo Variant, CNV Data
Mobidiag, Autobio Diagnostics to Form Joint Venture in China
Top Five Articles on GenomeWeb Last Week: 10x Genomics, Exosome Dx, Guardant Health, and More

The Scan

Corn's Complex Path

A genomic analysis of modern and ancient maize reveals a complicated domestication history, according to Reuters.

This Week in PLOS

In PLOS this week: MYRF variant linked to congenital diaphragmatic hernia, analysis of the "dragon's blood" red resin produced by traditional medicine plants, and more.

Five and Gone

CNBC reports that half of academic researchers leave after about five years.

From Within the Swamp

Researchers have used genetic analysis to confirm a new type of salamander, the New York Times reports.

Main menu